Recovery article

HGH Fragment 176-191 and Retatrutide Interaction: Monitor | Peptide Database

Compound Profiles HGH Fragment 176-191 Growth Hormone Fragment | Fat Loss Peptide Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone

By Recovery & Performance Peptides Editorial Team Published September 9, 2026

Compound Profiles

HGH Fragment 176-191

Growth Hormone Fragment | Fat Loss Peptide

Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone receptor, so it does not increase IGF-1 levels or interfere with glucose metabolism.

Retatrutide

Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes

Activates GLP-1 for appetite suppression, GIP for insulin sensitivity, and glucagon for increased energy expenditure and hepatic fat oxidation..

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take HGH Fragment 176-191 with Retatrutide?

Yes, but with caution. Both HGH Fragment 176-191 and Retatrutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.

Is HGH Fragment 176-191 and Retatrutide safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: insulin disrupting. Monitor accordingly.

What are the interactions between HGH Fragment 176-191 and Retatrutide?

Both HGH Fragment 176-191 and Retatrutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time HGH Fragment 176-191 and Retatrutide?

HGH Fragment 176-191 has a half-life of 15-20 minutes and Retatrutide has a half-life of ~6 days. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

COACH'S BOARD / KEY POINTS

HGH Fragment 176-191 and AOD-9604 are the same molecular structure. A 15-amino-acid sequence (positions 176–191) derived from the C-terminus of human growth hormone, with identical 1817 Da molecular weight and amino acid composition.
The AOD-9604 designation originated from clinical trials conducted by Metabolic Pharmaceuticals between 2004 and 2007, while Fragment 176-191 remains the standard biochemical nomenclature used in research supplier catalogs and academic publications.
Both compounds failed to achieve FDA approval for obesity treatment after Phase IIb trials showed insufficient weight loss efficacy (2.6% vs 1.8% placebo) despite acceptable safety profiles and no IGF-1 elevation.
The peptide retains lipolytic activity by activating beta-3 adrenergic receptors on adipocytes without binding to growth hormone receptors. Making it valuable for metabolic research isolating fat mobilization from anabolic growth signaling.
Lyophilized Fragment 176-191 maintains >95% purity for 21 days post-reconstitution when stored at 2–8°C in amber vials, but oxidation at cysteine residues accelerates degradation beyond 28 days or after freeze-thaw cycles.
Research labs should specify Fragment 176-191 or AOD-9604 based on protocol citation requirements rather than assuming functional differences. The molecular identity is identical across suppliers meeting GMP synthesis standards.

SOURCE / realpeptides.co ↗

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

HGH Fragment 176-191 Dosage Guide

There is currently no specific data available for hGH fragment 176-191 when administered as a nasal spray. Therefore, any intranasal dosing recommendations are extrapolated from studies and data pertaining to oral and injectable forms of this peptide fragment. Here is the most relevant dosing data on hGH fragment 176-191 in either oral form or injections: Orally administered hGH fragment 176-191 has shown promising results, particularly in weight loss studies. Trial data indicates significant weight loss with a daily intake of 1mg over a 12-week period [6]. Considering the aforementioned data on oral hGH fragment 176-191, the peptide is typically injected at a dose of 0.2-0.5mg/daily. Further, researchers may consider splitting the dosage into 2-3 administrations since clinical data with intravenous administration of hGH fragment 176-191 indicate a half-life of about 3 minutes. The half-life for subcutaneous administration remains undocumented. [15] In the absence of specific data for nasal spray application, the above insights may provide a starting point for researchers. Based on this data, experts suggest the following protocol for hGH fragment 176-191 nasal spray: hGH fragment 176-191 nasal spray dose: Researchers may consider initiating the study at 0.2mg/daily (200mcg/daily). Frequency: The frequency of administration is typically once or twice daily, although the available data is limited. Duration: Clinical studies involving oral hGH fragment 176-191 have lasted up t…

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

HGH Fragment 176-191 2mg - High-Quality Research Peptide

HGH Fragment 176-191, offered at 2mg, is a high-quality specialised research peptide developed for advanced scientific exploration in metabolism and endocrinology. This product is ideal for laboratory settings where precision and reliability are paramount. Product Name: HGH Fragment 176-191 2mg Catalogue Number: HGHF176191-2mg Molecular Formula: C78H125N23O23S2 Molecular Weight: 1817.1 g/mol Purity: ≥98% Form: Lyophilised Solid

RESEARCH

Research Indications

Increases fat oxidation and breakdown of stored triglycerides in adipose tissue without affecting glucose homeostasis. Reduces new fat synthesis and storage, complementing the lipolytic action for overall fat reduction. Promotes selective fat loss while preserving lean mass, particularly effective when combined with a caloric deficit and exercise.

Product & matchup locker

Linked catalog and comparison files.

Comparison

HGH Fragment 176-191 vs Full-Length Growth Hormone

HGH Fragment 176-191 vs Full-Length Growth Hormone Discover how HGH Fragment 176-191 compares to full-length HGH 191AA in fat metabolism, IGF-1 activity, and systemic effects. Cho…

View details →